Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.

New results from the OMICS study, which will be presented at ASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity/97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening. Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ranging between $30B and $75B in the U.S. alone